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Early and accurate detection of acute kidney injury (AKI) is
needed to prevent the progression to chronic kidney disease
and to improve outcome. Here we used capillary
electrophoresis–mass spectrometry to identify urinary
peptides predictive of AKI in a training set of 87 urine
samples longitudinally collected from patients in an intensive
care unit. Within this patient cohort, 16 developed AKI while
14 maintained normal renal function. The sequence of
twenty peptides significantly associated with AKI was
identified. They were found to be degradation products of
six proteins. These formed a diagnostic pattern. Peptides
of albumin, a-1-antitrypsin, and b-2-microglobulin were
upregulated but fragments of fibrinogen a and collagens
1 a(I) and 1 a(III) were downregulated in AKI. After cross-
validation of the training set, a good diagnostic performance
of the marker pattern was found with an area under the ROC
curve of 0.91. This was confirmed in a blinded validation set
of 20 patients in the intensive care unit and 31 allogeneic
hematopoietic stem cell transplantation patients, of which
13 had and 18 had not experienced an episode of AKI. In
comparison to more established markers of AKI such as
serum cystatin C and urinary kidney injury molecule-1,
interleukin-18, and neutrophil gelatinase associated-lipocalin,
the proteomic marker pattern was found to be of superior
prognostic value, detecting AKI up to 5 days in advance of
the rise in serum creatinine.
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Acute kidney injury (AKI) is a common and serious clinical
condition, especially in critically ill patients, increasing
mortality independent of other factors.1–3 Early and accurate
detection of AKI is crucial to enable early therapeutic
intervention and thereby to potentially improve the out-
come.4,5 In clinical practice, AKI is detected by changes in
serum creatinine, and sudden increments of creatinine
currently define AKI.6 However, there are major limitations
to the use of creatinine, as it is moderately accurate and
enables AKI detection only at a late stage.7–9 Therefore,
several new biomarkers have emerged in the last 5 years,
which promised earlier and more accurate AKI detection
in initial studies, including serum cystatin C (S-CysC),
kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18),
and neutrophil gelatinase-associated lipocalin (NGAL).10–13
However, validation in independent studies and larger, less-
specific patient cohorts presented conflicting results.14–17
Combined patterns of these biomarkers have recently been
suggested to perform better than single biomarkers.13,17,18
The diagnostic accuracy in predicting AKI of such combina-
tions is yet unknown, pinpointing the demand for novel,
predictive, and AKI-specific biomarkers.
Proteomic techniques have already proven to be a valuable
tool in the discovery of novel AKI markers.19–23 These studies
were, however, limited by small or selected patient cohorts,
less information on the diagnostic value and/or identity
of the biomarkers, and absence of blinded assessments.
The purpose of this study was to overcome these
challenges in clinical study design and to map the urinary
low-molecular-weight proteome of non-selected critically ill
patients who either developed AKI or maintained their
normal renal function by capillary electrophoresis–mass
spectrometry (CE–MS). We defined a biomarker pattern
based on naturally occurring polypeptides that allows
accurate and early detection of AKI and assessed its clinical
utility in two independent cohorts of patients with different
underlying etiologies of AKI.
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RESULTS
For biomarker definition, we analyzed urine samples of
30 intensive care unit (ICU) patients, of whom 16 developed
AKI (training set). Patients with and without AKI did not
substantially differ with respect to demographic and clinical
characteristics, as demonstrated in Table 1. In 14 patients,
AKI was defined by the serum creatinine criteria, and in
further 2 by serum creatinine and urine output criteria.
Worst AKI stages I, II, and III were present in 1, 4, and
11 patients, respectively. One patient (6%) developed oliguria
before the detection of AKI by Acute Kidney Injury Network
criteria, and 8 patients (50%) required renal replacement
therapy in the ICU training set. Initial urine samples
of AKI patients were collected at 3.4±1.0 days before the
diagnosis of AKI by serum creatinine as reference
standard, with a maximum of 5 days. Mean sample number
per patient was 2.4 in the AKI and 3.5 in the non-AKI ICU
group, with ranges of 1–5 and 1–6 days, respectively. Urine
samples were subjected to CE–MS to identify novel
biomarkers for AKI.
For multivariate statistical comparison of the data from
patients with and without AKI, only polypeptides with
identified peptide sequence were considered. Analysis
resulted in the definition of 64 potential biomarkers
with Benjamini and Hochberg adjusted P-values o0.05
(Supplementary Table S1 online). Initially, all peptides from
this pool were employed for pattern establishment and their
number was sequentially reduced by a take-one-out proce-
dure. A total of 16 urinary peptides were combined using the
support vector machine-based MosaCluster software24 to
generate an AKI-specific multimarker pattern. Sequence data
indicated that the 16 AKI-specific urinary peptides were
fragments of the serum proteins albumin, a-1-antitrypsin
(AAT), b-2-microglobulin (B2M), and fibrinogen a chain
(FIBA), and of the structural proteins collagen 1 a(I)
(COL1A1) and collagen 1 a(III) (COL1A3). The character-
istics of these peptides are presented in Table 2. All fragments
from albumin, AAT, and B2M were consistently upregulated
in AKI, whereas all peptides from COL1A1, COL1A3, and
FIBA were markedly downregulated. Sequence alignment of
the AKI-specific peptides with the corresponding parent
proteins demonstrated that fragments from albumin and
FIBA form clusters of overlapping sequences with predomi-
nantly identical N-terminus, and different C-terminus.
Therefore, we searched for additional differentially regulated
(Wilcoxon P-values o0.05) urinary peptides that originate
from the same proteins and protein regions.
This approach resulted in the identification of four
additional peptides that improved the performance of the
support vector machine model from 73/87 to 82/87 correctly
classified samples in the training set. Cross-validated
classification (as described by Dakna et al.25) of the training
samples with the final 20 peptide marker pattern yielded an
area under the curve (AUC) value of 0.91 for AKI detection
in receiver operating characteristic curve with the 95%
confidence interval (CI) being 0.83–0.96. Sensitivity of 92%
(95% CI 79–98%) and specificity of 90% (95% CI 78–97%)
were achieved. As presented in the Supplementary Figure S1a
online, for three AKI and three non-AKI ICU patients of the
training set with consecutively daily urine samples available,
the urinary peptide pattern consistently discriminated well
between AKI and non-AKI over a time period of 4 days
before AKI.
To validate reliability in AKI detection, the proteomic
marker pattern was subsequently applied to 20 ICU patients
of a blinded phase II study cohort. Patients of this ICU
validation set did not significantly differ in their demo-
graphic and clinical data from the patients in the training set
Table 1 | Characteristics of patients with and without AKI in the training and the two validation sets
ICU training set ICU validation set HSCT validation set
Healthy
AKI Non-AKI P STD AKI Non-AKI P STD AKI Non-AKI P STD controls
Patients/samples (n) 16/38 14/49 9/9 11/11 13/16 18/22 28
Age (years) 66±13 69±14 0.21 0.22 63±15 68±12 0.49 0.37 53±13 51±13 0.84 0.00 51±11
Gender (female/male) 15/22 18/30 0.95 3/6 3/8 1.00 6/7 6/12 0.47 6/22
Diabetes mellitus, n (%) 6 (38) 4 (29) 0.61 3 (33) 2 (18) 0.85 ND ND 0
Chronic kidney disease, n (%) 5 (31) 3 (21) 0.54 2 (22) 2 (18) 0.74 ND ND 0
APACHE II score (points) 23±5 24±4 0.17 0.22 24±3 23±4 0.63 0.29 ND ND NA
S-creatinine at baseline (mmol/l) 88±14 89±12 0.85 0.08 93±14 91±15 0.78 0.14 90±22 93±24 0.36 0.13 97±12a
Estimated glomerular filtration rate
at baseline (ml/h per 1.73m2)
72±18 71±17 0.98 0.06 69±17 71±19 0.56 0.11 72±27 75±28 0.42 0.10 73±15
Urine output at baseline (ml/day) 2.2±0.6 2.4±0.7 0.33 0.31 2.3±0.5 2.4±0.6 0.81 0.16 ND ND
Etiology of AKI (n)
Ischemia 5 2 1
Nephrotoxic 1 NA 0 NA 3 NA NA
Sepsis 3 2 7
Combination 7 5 2
Worst AKI stage, n (I/II/III) 1/4/11 0/3/6 NA
Renal replacement therapy, n (%) 8 (50) 4 (44)
Oliguria, n (%) 1 (6) 1 (11)
Abbreviations: AKI, acute kidney injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; HSCT, hematopoietic stem cell transplantation; ICU, intensive care unit;
NA, not available; ND, not determined; STD, standardized difference. Data are presented as mean±s.d.
aS-creatinine at baseline was significantly lower in AKI cases and non-AKI controls of the ICU training set when compared with healthy controls (P=0.011 and P=0.007,
respectively). These differences might be attributed to lower muscle mass, less physical mobility, and high rate of sepsis of ICU patients compared with healthy subjects.
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(Table 1). In all nine patients, AKI was defined by serum
creatinine criteria. Data on worst AKI stages and required
renal replacement therapy are presented in Table 1. Upon
unblinding, 8 of 9 patients with AKI and 9 of 11 patients
without AKI were correctly identified. As shown in Figure 1,
this yielded an AUC of 0.84 (95% CI 0.61–0.96), a sensitivity
of 89% (95% CI 52–98%), and a specificity of 82% (95% CI
48–97%). For further validation, the AKI-specific pattern was
applied to a second validation set of 31 patients after
allogeneic hematopoietic stem cell transplantation (HSCT) as
different underlying etiology of AKI. Patients of the HSCT
validation set with and without AKI also did not significantly
differ in demographic and clinical characteristics (Table 1). In
this cohort, 13 patients developed AKI. As indicated by an
AUC of 0.90 (95% CI 0.76–0.97), a sensitivity of 94% (95%
CI 70–99%), and a specificity of 82% (95% CI 60–95%), the
AKI-specific biomarker pattern also performed well to detect
AKI in this non-ICU validation cohort (Figure 1). Of note,
urine samples in HSCT patients were spontaneously voided
and not obtained from indwelling catheter as in ICU patients.
This is of interest as urine collection from indwelling
catheters may potentially alter the urinary proteome by
protein adsorption or prolonged storage in the catheter
collection bag. The validity of this biomarker pattern was
further supported by the finding that none of the 28 healthy
controls was diagnosed false positive for AKI.
To test whether the AKI-specific biomarker pattern
performed differently at varying AKI stages, we compared
ICU patients with AKI stages 1 and 2 (n¼ 17) with those in
stage 3 (n¼ 30). Comparison of classification factors between
these groups revealed no statistically significant differences of
classification by the urinary peptide pattern depending on
the severity of AKI (data not shown). To investigate how the
AKI-specific biomarker pattern performed during the
recovery phase of AKI compared with serum creatinine, the
longitudinal course of classification by the AKI marker panel
was monitored for three HSCT patients, for whom multiple
measurements at the time of AKI were available. As presented
in the Supplementary Figure S1b online, the AKI-specific
biomarker pattern permitted earlier detection of AKI. The
AKI-specific biomarker pattern dropped below the cutoff
value for AKI diagnosis in parallel to the decrease of serum
creatinine. This suggests an equivalent diagnostic value of
both markers for AKI recovery.
Table 2 | Characteristics of urinary polypeptides included in the AKI marker pattern
Training set
Mass
(Da)
CE time
(min) Protein Sequencea AA Remarks
Mean
counts
AKI
Frequency
AKI
Mean
counts
non-AKI
Frequency
non-AKI P AUC
1439.66 29.82 AAT TIDEKGTEAAGAMF 363–376 - Fragments C-terminally from the
extended loop containing the active
site
752 0.50 148 0.27 0.0395w 0.64
912.54 20.06 KVVNPTQK 411–418 126 0.50 39 0.13 0.0057w 0.68
2080.99 20.20 ALB DAHKSEVAHRFKDLGEEN 25–42 - N-terminal sequence of mature ALB 6580 0.44 729 0.36 0.0138z 0.59
2356.16 19.52 DAHKSEVAHRFKDLGEENFK 25–44 - Fragments with identical
N-terminus, but different C-terminus
2801 0.47 346 0.20 0.0109w 0.66
2427.19 19.58 DAHKSEVAHRFKDLGEENFKA 25–45 1512 0.45 339 0.15 0.0109w 0.66
2540.28 19.68 DAHKSEVAHRFKDLGEENFKAL 25–46 2820 0.47 654 0.23 0.0340w 0.64
2639.35 19.78 DAHKSEVAHRFKDLGEENFKALV 25–47 1371 0.22 247 0.09 0.0292z 0.59
1081.66 20.73 B2M IQRTPKIQV 21–29 - Fragments, but not full-length
B2M, were found differentially
regulated in AKI
896 0.45 207 0.18 0.0395w 0.63
1300.59 28.53 VSGFHPSDIEVD 47–58 - Peptides with overlapping
sequence motifs
980 0.39 29 0.12 0.0165w 0.64
2603.30 20.07 LKNGERIEKVEHSDLSFSKDWS 60–81 20 452 0.45 5411 0.40 0.0226z 0.58
2716.38 20.19 LLKNGERIEKVEHSDLSFSKDWS 59–81 144 368 0.63 24 126 0.52 0.0423w 0.65
1654.79 23.13 COL1A1 SpGEAGRpGEAGLpGAKG 522–539 - Peptides 522–539 and 798–810
also detected in plasma
911 0.68 2872 0.98 0.0004w 0.78
1737.78 31.00 TGSpGSpGPDGKTGPPGpAG 541–560 939 0.63 3298 0.82 0.0078w 0.73
1250.55 27.93 ApGDRGEpGPpGP 798–810 16 430 0.97 25 594 1.00 0.0083w 0.71
3359.57 31.90 PpGADGQPGAKGEpGDAGAKGD
AGPpGPAGPAGPpGPIG
816–854 154 0.16 437 0.55 0.0106w 0.68
2942.30 22.23 ESGREGApGAEGSpGRDGSpGAK
GDRGETGP
1011–1041 1934 0.68 3970 0.92 0.0085w 0.71
2007.94 22.10 COL1A3 DGESGRPGRPGERGLPGPPG 230–249 2781 0.82 5923 0.96 0.0047w 0.74
1825.78 19.41 FIBA DEAGSEADHEGTHSTKR 605–621 - Fragments with identical
N-terminus, but different C-terminus
511 0.37 1593 0.88 0.0004w 0.78
1882.80 20.14 DEAGSEADHEGTHSTKRG 605–622 - Peptides 605–622 and 605–628 also
detected in plasma
11 553 0.87 25 962 0.90 0.0083w 0.72
2559.18 19.41 DEAGSEADHEGTHSTKRGH
AKSRP
605–628 6342 0.61 5184 0.49 0.0399z 0.58
Abbreviations: AA, amino acid; AAT, a-1-antitrypsin; AKI, acute kidney injury; AUC, area under curve; B2M, b-2-microglobulin; CE, capillary electrophoresis; COL1A1, collagen 1
a(I); COL1A3, collagen 1 a(III); FIBA, fibrinogen a chain.
aLower case p indicates hydroxyproline.
wBenjamini and Hochberg adjusted P-values.
zUnadjusted Wilcoxon P-values.
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In Figure 2, the compiled CE–MS profiles of AKI marker
distribution in patients with and without AKI of the ICU
training, the ICU validation, and the HSCT validation sets
were compared. Mean excretion levels of individual peptides
in the compiled CE–MS spectra of case and control patients
differed to some extent between the ICU and HSCT cohorts.
This is not unexpected as etiology, comorbidity, and severity
of illness vary in ICU and HSCT patients and indicate the
ability of the AKI-specific marker pattern to differentiate
between AKI and non-AKI in ICU and HSCT patients
independently of these potential confounders.
The classification performance of urinary proteome
analysis was compared with urinary NGAL, IL-18, and
KIM-1, and the serum marker S-CysC. Receiver operating
characteristic analysis on the ICU and HSCT validation sets
revealed low classification accuracy for the proposed single
AKI markers, not reaching statistical significance in any of
these two cohorts (Figure 3). Even when both patient cohorts
were combined, insignificant classification performance was
obtained (data not shown).
In the following, we analyzed early diagnostic efficacy of
the AKI marker pattern. For this purpose, the nine AKI
patient samples of the ICU validation set were subdivided
into available samples of days 5 and 4 (5/4) and days
3 to 0 (3 to 0) before AKI. The 11 non-AKI samples of the
ICU validation set served as reference group in both
comparisons. As presented in Figure 4, the biomarker pattern
performed equally well in the two subgroups, as indicated
by an AUC for AKI detection of 0.86 (95% CI 0.59–0.97) in
the 5/4 group and 0.82 (95% CI 0.54–0.96) in the 3 to 0
group. Compared with the proteomic marker pattern, a
statistically significant rise in the levels of proposed single
AKI biomarkers was first detected for S-CysC at day 3,
whereas NGAL showed only significance on day 2, and
KIM-1 and IL-18 on days 1 and 0 before AKI (Supple-
mentary Figure S2 online). In the case of the single AKI
biomarkers, receiver operating characteristic analysis was
extended to all samples of AKI and non-AKI ICU patients to
obtain statistical confidence.
In 43 ICU patients, data on albuminuria before AKI
episodes were available. The odds ratio to develop increased
urinary excretion of albumin fragments when having
demonstrated albuminuria was 1.2 (95% CI 0.8–1.7;
P¼ 0.72). From 17 ICU patients with established AKI, serum
creatinine values were available for 43 months of follow-up
after AKI episode. In this subgroup, a downregulation of
COL1A1 and COL1A3 fragments was associated with the
development or progress of chronic kidney disease (CKD)
subsequent to AKI with an odds ratio of 3.0 (95% CI 1.3–7.4;
P¼ 0.009).
DISCUSSION
We developed a multivariate, AKI-specific biomarker pattern
consisting of 20 urinary polypeptides. The pattern detects the
development of AKI up to 5 days earlier than serum
creatinine, the current standard reference for AKI detection.
Our results were confirmed by validation in two indepen-
dent, blinded ICU and cross-sectional HSCT patient cohorts.
In addition, our data suggest that this AKI-specific biomarker
pattern consistently discriminates well between AKI and
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Figure 1 |Receiver operating characteristic (ROC) curves of the acute kidney injury (AKI)-specific biomarker pattern to detect
AKI in the intensive care unit (ICU) training set (left), in the ICU validation set (middle), and in the hematopoietic stem cell
transplantation (HSCT) validation set (right). The table presents the distribution of AKI patients in the different cohorts, areas
under the ROC (AUC), and 95% confidence intervals (CI). The 95% CIs in the ROCs are indicated by dashed lines.
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non-AKI over a time period of several days before AKI, that
the pattern does not change depending on the severity of
AKI, and that it has equivalent diagnostic value for AKI
recovery in comparison to serum creatinine.
The sequences of all 20 polypeptides were known and the
fragments could be attributed to 4 serum and 2 structural
proteins with a wide range of regulatory functions. So far,
only full-length B2M and peptide fragments have repeatedly
been reported as urinary biomarkers of AKI.19–21,26 The alter-
ations of these polypeptides identified in urine may be
attributed to differences in production rates, increased
assembly into filaments, increased proteolysis in the plasma
or urine, renal dysfunction, or a combination of the above.
This study does not permit to distinguish between these
various mechanisms and might be an origin for systematic
investigation of the pathophysiological implications of these
markers.
The most pronounced change detected in this study was
the upregulation of urinary B2M fragments. Renal tubular
epithelial cell injury is indicated by increased urinary
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Figure 2 |Peptide pattern distinguishing patients with and without acute kidney injury (AKI). Compiled capillary electrophoresis–mass
spectrometry (CE–MS) profiles of the 20 urinary polypeptides included in the AKI-specific biomarker pattern in the intensive care unit
(ICU) training set (a, b), ICU validation set (c, d), and hematopoietic stem cell transplantation (HSCT) validation set (e, f). Polypeptide
profiles of AKI patients are presented on the right, those of patients without AKI (non-AKI) on the left. Normalized CE-migration
time (range 10–50min) on the x axis is plotted against log molecular mass (range 0.8–10 kDa) on the y axis. Mean signal intensity of
polypeptides is encoded by peak height.
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Figure 3 |Acute kidney injury (AKI) classification of the intensive care unit (ICU) and hematopoietic stem cell transplantation (HSCT)
validation set based on either the AKI marker pattern or detection of levels of urinary neutrophil gelatinase-associated lipocalin
(NGAL; in ng/mg U-Crea), urinary interleukin-18 (IL-18; in pg/mg U-Crea), urinary kidney injury molecule-1 (KIM-1; in pg/mg U-Crea), or
serum cystatin C (S-CysC; in mg/l). Comparison of receiver operating characteristic (ROC) curves (upper panel) and table of ROC-derived area
under the curve (AUC) values for classification of the ICU and HSCT validation sets with the AKI marker pattern or single AKI biomarkers
(lower panel).
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Figure 4 | Early diagnostic efficacy of the acute kidney injury (AKI) marker pattern at different days before AKI detection by serum
creatinine. The nine AKI patient samples of the intensive care unit (ICU) validation set were subdivided into available samples of days 5 and4
and days3 to 0 before AKI. In both receiver operating characteristic (ROC) curves, the 11 non-AKI samples of the ICU validation set were used as
negative reference group. As indicated by identical ROC curve characteristics, the AKI marker pattern performed equally well in both groups.
Kidney International (2010) 78, 1252–1262 1257
J Metzger et al.: Proteomic marker pattern for early and accurate AKI detection o r ig ina l a r t i c l e
excretion of B2M.27 After passage of the glomerular filter,
B2M is taken up from the proximal tubule by megalin
and cubilin-mediated endocytosis.28 In experimental AKI,
increased urinary B2M could be attributed to impaired
megalin and cubilin expression.29 Moreover, accelerated
fragmentation of accumulated urinary B2M may occur
because of an inflammation-induced increase in tubular
proteolytic activity.30 The same mechanism might also
account for the observed upregulation of urinary albumin
fragments in AKI patients, as albumin and most likely
albumin fragments are also filtered by the glomerulum and
reabsorbed by megalin and cubilin.31 Increased levels of
albumin fragments have already been described in nephrotic
syndrome,32 where fragmentation was primarily discovered
not only in plasma but also in urine.
AAT is a major acute-phase protein with various anti-
inflammatory and anti-apoptotic effects, as could be shown
in an experimental model of renal ischemia/reperfusion
injury.33 In various animal models of AKI, cytokine-mediated
proinflammatory responses have a major role in the
pathophysiology of AKI.34 Human AKI is associated with
increased levels of proinflammatory cytokines and acute-
phase proteins.35,36 Although no previous data on urinary
AAT and its fragments in AKI have yet been published, AAT
fragments were detected in small amounts in plasma and
urine of healthy individuals and in larger amounts in patients
with nephrotic syndrome.32 Fragmentation of AAT may
occur in plasma during increased supply and degradation of
AAT-protease complexes as well as in urine because of
increased activity of microenvironmental proteinases, such as
matrix metalloproteinase (MMP)-9, in response to tubular
damage.13,37,38 With respect to the observed decrease in
collagen fragments, it was found that intact AAT affects
remodeling of extracellular matrix (ECM) mainly through
binding to elastase,39 thereby preventing its capacity to cleave
tissue inhibitor of metalloproteinases.40 The balance between
tissue inhibitor of metalloproteinase and MMPs is crucial in
maintaining ECM homeostasis of constant assembly and
disassembly.41 A tissue inhibitor of metalloproteinase-
mediated inhibition of MMP activity may therefore account
for decreased urinary excretion of COL1A1 and COL1A3
fragments, as less collagen filaments from the ECM will be
cleaved. This hypothesis is in line with observations that renal
interstitial fibrosis is associated with reduced levels of
MMPs and ECM accumulation in experimental AKI.42–45
Furthermore, these histological findings are in accordance
with recent clinical observations that AKI leads to CKD in a
substantial proportion of patients.46 Interestingly, we
obtained a significant inverse correlation of lowered urinary
excretion of collagen fragments and CKD development or
progression post AKI.
Furthermore, AAT promotes thrombin-mediated conver-
sion of fibrinogen to fibrin by inhibition of activated protein
C.47 This is in accordance with our observation of reduced
levels of FIBA peptides. Shifting the balance toward coagula-
tion, the inhibitory effects of AAT provide an explanation
for decreased levels of activated protein C in AKI,48,49 and
microvascular fibrin deposits in experimental AKI.50,51
In summary, changes in the fragments of all six proteins
constituting the biomarker pattern have a reasonable
biological rationale, and some may not only be markers,
but surrogates of underlying pathophysiology in AKI. In this
context, the site where the AKI-specific peptide markers
originate is of special interest. The detection of several of the
urinary COL1A1 and FIBA fragments included in the AKI
pattern in human plasma (as noted under the remarks in
Table 2) at least proves that their occurrence is not restricted
to urine alone and excludes the urinary bladder as possible
site of their origin. Also of note is the finding that all AKI-
relevant AAT peptides originate from the C-terminal region
that contains the active site in an extended loop structure that
is indicative for MMP cleavage in injured tissue.52–55 An open
question is, however, whether these peptides occur in the
plasma because of release of proteolytic fragments from tissue
or vascular endothelium into plasma/urine or because of
tubular reabsorption of proximal tubular degradation products.
A decrease in the abundance of collagen fragments was
already observed in proteomic studies investigating chronic
kidney diseases by CE–MS.56–58 As previously suggested,
changes in the urinary proteome may reflect primary
pathophysiological alterations as well as response of the
organism to disease.57 Although there are peptides generally
affected by kidney injury, there are others that are more specific
for particular disease processes, that is, tubular capillaritis,
vasculitis, or IgA nephritis. Naturally occurring peptides
resemble surrogates of specific proteases and are thus subject
to a higher degree of variance than their protein counterparts.
In this study, a partial synergism was observed between acute
and chronic kidney failure, as both types lead to decreased
excretion of peptides from type I collagens, which was
attributed to altered ECM turnover and connected to increased
risk of AKI patients to develop CKD.59 Using CE–MS, it cannot
be resolved whether the two diseases share the same underlying
mechanism. However, a comparative analysis on peptides
included in the AKI and CKD marker panels revealed that two
of the five collagen 1 a(I) peptides in AKI similarly regulated in
patients with macroalbuminuria. Not unexpectedly, another
overlap between AKI and CKD exists for albumin-derived
fragments. Therefore, in a future study it has to be determined
to which extent pre-existing CKD interferes with AKI diagnosis
by the proteomic marker panel.
We applied the currently widely accepted AKI definition
given by Mehta et al.,6 permitting comparison of our
findings with other proteomic and biomarker stu-
dies.10,12,13,15–17,22,23,26 The extend of the time frame obtained
by early AKI diagnosis with the presented biomarker pattern
substantially exceeds that of previous findings using only
single biomarkers.10,12 This is consistent with previous
studies that showed that urinary NGAL, IL-18, KIM-1, and
S-CysC permitted detection of AKI 12–36 h earlier than
serum creatinine, but by far not as early as with our
biomarker pattern, providing up to 5 days of valuable time
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for clinical interventions before AKI defined by serum
creatinine.10–12,14,16,17,60,61 Although initial studies describing
these single biomarkers reported good or excellent diagnostic
accuracy, there have been conflicting results with poor and
fair accuracy in some subsequent studies.10–12,14–17,60,61
Although our study was not powered to test the accuracy
of these single biomarkers, our findings of moderate
diagnostic accuracy of urinary NGAL, IL-18, KIM-1, and
S-CysC are consistent with some previous reports.14–17,60
Consideration of a biomarker as clinically relevant
requires confirmation in independent cohorts of the target
population.62 We therefore analyzed samples from an
unselected group of critically ill patients with several causes
of multifactorial AKI. The accuracy of AKI detection in both
ICU and HSCT validation sets demonstrated general
applicability of the biomarker pattern independent of AKI
etiology, comorbidity, severity of illness, medical treatment,
and recruiting center. Because of the diversity of pathological
processes leading to AKI, it is unlikely that a single marker is
capable to serve as reliable predictor in every case. Hence,
combining 20 biomarkers enables establishment of a broadly
applicable pattern, compensating potential biological, pre-
analytical, and analytical variability of single biomarkers.
In conclusion, the results presented in this study suggest
that the identified AKI marker pattern enables accurate
detection of AKI in patients 5 days before the rise of serum
creatinine, providing a substantial time frame to initiate
established therapeutic interventions to prevent AKI or
its progression, potentially improving clinical outcome. As
current MS technology is inappropriate for routine ICU use
because of cost-intensive and time-consuming sample
processing and analysis requirements, a future step is to
switch to an alternative point-of-care analytical platform,
allowing timely monitoring of patients in the ICU by the
presented AKI-specific biomarker pattern.
MATERIALS AND METHODS
Patients
Adult patients at high risk for AKI admitted to three ICUs at the
University Hospital Essen between January and October 2006 served
as training set for the identification of early AKI markers and the
establishment of the AKI marker panel. The high risk for AKI was
defined by at least two of following criteria: age 480 years, diabetes,
cardiogenic or hemorrhagic shock, severe sepsis or septic shock,
nephrotoxic medication, rhabdomyolysis, intra-arterial contrast,
decompensated liver cirrhosis, and coronary artery bypass grafting
with heart valve replacement. The definitions are provided in the
Supplementary Table S2 online. AKI was defined either by a serum
creatinine increase of X50% or X0.3 mg/dl from stable baseline
values within 48 h and/or by a reduction in urine outputo0.5 ml/kg
per hour for 46 h, and AKI stages as recently proposed.6
We considered the baseline serum creatinine values as the first
measurements performed after hospital admission. We excluded
patients with (1) pre-existing advanced CKD as defined by an
estimated glomerular filtration rate o30 ml/min per 1.73 m2,
(2) pre-renal azotemia defined as rapid reversibility of AKI following
adequate fluid resuscitation, (3) post-renal AKI diagnosed by
urinary tract obstructions in ultrasound, and (4) patients who
developed AKI in p48 h after admission to make early AKI
detection meaningful. The glomerular filtration rate was estimated
according to the recalculated equation derived from the Modifica-
tion of Diet in Renal Disease study.63 CKD was defined as an
estimated glomerular filtration rateo60 ml/min per 1.73 m2 present
for 43 months before as well as at hospital admission, albuminuria
as urinary albumin excretion X30 mg/day, CKD development as a
decrease in estimated glomerular filtration rate from 460 before
hospital admission to o60 ml/min per 1.73 m2 after hospital
discharge, and CKD progress as deterioration by at least 1 CKD
stage from prehospital admission to posthospital discharge. Patients
not developing AKI (n¼ 14) served as controls. In total, 82 patients
were screened of whom 52 were excluded by the criteria described
above. Daily urine and serum samples were collected between 0700
and 0800 hours starting from ICU admission until discharge.
All urine samples were obtained from indwelling bladder catheters
after emptying the urine collection bags at 0600 hours. In patients
with AKI, ‘day 0’ was the day the AKI criteria were fulfilled for the
first time. In controls, urine was analyzed from the samples collected
for a maximum observation period of 6 days, starting from the first
day of admission to ICU (49 samples in total). Urine sample were
immediately frozen and stored at 80 1C until analysis.
A second, blinded set of ICU patients was studied for validation
of the AKI marker panel that consisted of all consecutive adults
admitted to the ICUs between August and September 2007. In total,
51 patients were screened, of whom 20 were included in the ICU
validation set. Inclusion and exclusion criteria were the same as
described above.
A second validation set consisted of patients post HSCT,
collected at the Hannover Medical School from February to May
2008. This cohort was assessed cross-sectionally, and samples were
regarded AKI positive by a serum creatinine rise X50% within 48 h.
In the HSCT cohort and in a healthy control group (n¼ 28),
spontaneously voided second morning urine samples were collected.
The local ethics committees approved the study, and all subjects
gave informed consent. The study adhered to the Helsinki Declaration.
CE–MS analysis
A 0.7 ml urine aliquot was thawed and diluted with 0.7 ml 2 M urea,
10 mmol/l NH4OH containing 0.02% sodium dodecyl sulfate. Proteins
420 kDa were removed by ultracentrifugation through Centrisart filters
(Sartorius, Goettingen, Germany) at 3000 r.c.f. until 1.1 ml filtrate was
obtained. The filtrate was desalted on a PD-10 column (GE Healthcare,
Uppsala, Sweden) equilibrated in 0.01% aqueous NH4OH (Roth,
Karlsruhe, Germany). Samples were lyophilized and stored at 4 1C until
resuspension in high performance liquid chromatography (HPLC)-grade
H2O to a final protein concentration of 0.8mg/ml before analysis. Analysis
and data processing were performed in accordance with current
guidelines for clinical proteome analysis64,65 using a P/ACE MDQ
capillary electrophoresis system (Beckman Coulter, Fullerton, CA) on-
line coupled to a Micro-TOF MS (Bruker Daltonic, Bremen,
Germany).66,67 Spectra were accumulated every 3 s over an m/z-range
of 350–3000 Da. Details on accuracy, precision, selectivity, sensitivity,
reproducibility, and stability of the CE–MS method have been reported.67
Data processing
Mass spectral ion peaks representing identical molecules at different
charge states were deconvoluted into single masses using
MosaiquesVisu.68 The software employs probabilistic clustering
and uses both isotopic distribution and conjugated masses for charge-
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state determination of peptides/proteins. For peak definition, signals
with z41 observed in a minimum of three consecutive spectra with a
signal-to-noise ratio of at least four were considered. The resulting peak
list characterizes each polypeptide by its molecular mass, CE-migration
time, and ion signal intensity (amplitude). Data were normalized using
a calibration method for CE-migration time and ion signal intensity on
the basis of ‘internal standard’ peptides, which we proved to be
superior over creatinine normalization.24,69 All peptides were deposited,
matched, and annotated in a Microsoft SQL database (Unterschleis-
sheim, Germany). Peptides were considered identical when mass
deviation was o50 p.p.m. for small peptides or 75 p.p.m. for larger
peptides and proteins. Deviation of migration time was o0.45 min.
Generation of AKI-specific polypeptide pattern
An AKI-specific polypeptide biomarker model was generated by
combination of peptides that are differentially distributed between
case and control samples using the support vector machine-based
MosaCluster software.24 In support vector machine, a sample is
regarded as a p-dimensional vector with p being the number of
peptides included in the pattern. The algorithm constructs a (p-1)-
dimensional separation plane between case and control vectors.
From all possible hyperplanes that separate cases and controls, the
one with the largest distance to the nearest data points on both sides
is selected. Classification is performed by determining the Euclidian
distance of the data point to the maximal margin of the hyperplane
and assignment of a positive or negative value depending on which
side of the hyperplane, case or control, the vector is located.
Sequencing of peptides
Peptides were separated by nanoflow reverse phase-HPLC (Agilent
1100 (Agilent Technologies, Boblingen, Germany); flow split by tee to
B60 nl/min) and introduced into an electron transfer dissociation-
capable Finnigan LTQ quadrupole linear ion trap (Thermo Scientific,
Bremen, Germany) via nano-electrospray ionization as previously
described.70 The resulting tandem mass spectrometry data were
submitted to MASCOT (Matrix Science, London, UK) for a search
against human entries in the MSDB (Mass Spectrometry protein
sequence DataBase) Protein Database with an accepted parent ion
mass deviation of 50 p.p.m. and an accepted fragment ion mass
deviation of 500 p.p.m. Only search results with a MASCOT peptide
score 420 were included. An additional search was employed against
the NCBI human non-redundant database using OMSSA
(http://pubchem.ncbi.nlm.nih.gov/omssa/).
Enzyme-linked immunosorbent assay and laboratory tests
Assays for human NGAL and KIM-1 were from R&D Systems
(Wiesbaden, Germany), and the human IL-18 enzyme-linked
immunosorbent assay kit was from MBL International (Woburn,
MA). Urinary samples were diluted 20-fold in calibrator diluents for
measurement of NGAL or used undiluted for the IL-18 and KIM-1
assays. Enzyme-linked immunosorbent assay measurements were
carried out according to the manufacturer’s instructions. To eliminate
the influence of variable urine flow, urinary levels of NGAL, KIM-1,
and IL-18 were normalized to urinary creatinine. Serum creatinine was
measured with an enzymatic colorimetric assay (Roche Diagnostics,
Mannheim, Germany), S-CysC by immunonephelometry (Dade Behring,
Marburg, Germany).
Statistical analysis
Sensitivity, specificity, 95% CI, and AUC were calculated based on
receiver operating characteristic analysis using MedCalc version
9.5.2.0 (MedCalc Software; Mariakerke, Belgium). After testing for
normal distribution, continuous data were compared using Student’s
t-test or Mann–Whitney rank-sum test, and categorical data were
compared using w2 or Fisher’s exact test. A two-sided P-value ofo0.05
was considered statistically significant. P-values were calculated using
the log-transformed intensities and the Gaussian approximation to
the t-distribution. To adjust for multiple testing, the false discovery
rate was controlled according to Benjamini and Hochberg.71
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